Business context and reporting period
Filing identity: Despite the request metadata naming ProKidney Corp., this is Social Capital Suvretta Holdings Corp. III’s (Nasdaq: DNAC) Form 10-K, not an operating-company 10-K for ProKidney. It covers the period from the SPAC’s incorporation on February 25, 2021 through December 31, 2021; the filing was signed March 23, 2022.
The registrant was a blank-check company formed to complete a business combination and had no operating business. On January 18, 2022, after the reporting period, it agreed to combine with ProKidney LP. The 10-K does not give effect to that proposed transaction or provide ProKidney’s operating results.
Financial results and condition
| Metric | Reported amount |
|---|---|
| Operating revenue | None |
| Formation and operating costs | $2.33 million |
| Trust-account interest income | $8,324 |
| Net loss | $2.32 million; $0.11 per Class A and Class B share |
| Cash outside the trust at year-end | $440,488 |
| Trust-account securities at year-end | $250.01 million |
| Working-capital deficit | $935,119 |
| Cash used in operating activities | $1.21 million |
The trust balance was held principally in U.S. Treasury-focused money-market funds and was generally reserved for a business combination or shareholder redemptions. Total assets were $251.20 million; total liabilities were $9.58 million, including a $7.70 million deferred underwriting fee payable upon a completed combination. The filing reports no long-term debt. No profit margin is meaningful because the company had no operating revenue.
Changes, transaction, and outlook
This is the company’s first reporting period, so there is no comparable prior-year operating period. The IPO closed July 2, 2021, raising $250 million from public shares and $6.4 million from private-placement shares; $250 million was placed in trust. The company reported $12.48 million of IPO-related costs.
The proposed ProKidney transaction contemplated a $575 million PIPE at $10 per share, subject to conditions, alongside trust proceeds remaining after redemptions, underwriting commissions, and certain transaction expenses. The transaction terms include earnout rights vesting in three tranches if the share price reaches $15, $20, and $25, or upon certain change-of-control events. Completion remained subject to conditions; the SPAC’s business-combination deadline was July 2, 2023, subject to possible extension. The filing provides no operating guidance or forecast for the combined company.
Risks, contingencies, and unusual items
- The auditor’s report includes a going-concern explanatory paragraph: limited cash outside trust and the working-capital deficit raise substantial doubt about the company’s ability to continue for a reasonable period without additional funding. Sponsor and affiliate loans were possible but not committed.
- Management concluded disclosure controls were ineffective because of a material weakness in accounting for complex financial instruments. The company described remediation efforts; the filing also refers to a resulting restatement but does not clearly specify its scope or amounts in the text provided.
- Shareholder demand letters alleged deficiencies or omissions in the ProKidney transaction disclosure statement. The company considered the allegations meritless; no litigation was known as of the filing date.
- Key SPAC risks include shareholder redemptions reducing cash available at closing, creditor claims against trust funds, failure to complete a transaction by the deadline, and potential dilution or debt financing. The sponsor’s trust indemnity may be limited by its ability to pay.
- Management and affiliates had roles in other SPACs and investment businesses, creating potential conflicts over time and allocation of business opportunities. COVID-19 and market conditions could also affect financing, due diligence, and transaction completion.
Most important facts for investors to verify
- Confirm the filing entity: DNAC, not ProKidney Corp.; review ProKidney’s separate filings for its financial performance, cash needs, and operating risks.
- Check subsequent filings for the proposed combination’s status, actual redemptions, PIPE funding, minimum-cash conditions, transaction expenses, and final capitalization.
- Review the material-weakness remediation and any restatement disclosures, and assess whether controls were later found effective.
- Verify available cash outside the trust, outstanding accrued expenses, and any sponsor or affiliate funding; trust assets are not ordinary operating liquidity.
- Read the transaction disclosure statement and current filings for updated risks, legal matters, dilution, earnout terms, and the consequences of shareholder redemptions.